No Data
No Data
Open source securities: first-time buy rating for hutchmed (china) (00013), entering the global harvest period in the solid tumor field.
According to the research report released by Kaiyuan Securities, bullish-rated Hutchmed (China) for the first time, expecting a net income attributable to shareholders of -648 million/18 million/1.131 billion yuan from 2024 to 2026. Fruquintinib has been approved for marketing in the United States in 2023 and is commercially sold overseas by Takeda Pharmaceutical. Multiple indications of several products in the pipeline are expected to be gradually approved in the global market in the coming years, and the company has entered the global harvest period. The bank is bullish on the company's long-term development. The pipeline is calculated based on the already approved and expected pipeline.
HK stocks abnormal | Hutchmed (China) Medicine (00013) rose more than 5%. The company recently launched the HMPL-506 phase I clinical trial for hematologic malignancies.
Hutchmed (China) (00013) rose more than 5%, as of press time, up 5.11%, reported HKD 29.85, with a turnover of HKD 33.2161 million.
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia
Hutchmed (HCM) said late Thursday it has begun a phase 1 trial of its drug candidate, HMPL-506, which is intended to treat patients with hematological malignancies, such as acute myeloid leukemia. The
Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two p
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins
Hutchmed (china) (HKG:0013) began Phase І clinical trial of its cancer drug HMPL-506 with the first patient administered the first dose on May 31, according to a Friday filing on the Hong Kong bourse.
Hutchmed (China) (00013.HK): Has launched a phase I clinical trial in China for Menin inhibitor HMPL-506 to treat hematologic malignancies.
On June 7th, Gelunhui announced that hutchmed (china) has initiated a phase I clinical trial in China for HMPL-506 for the treatment of hematologic malignancies. The first patient received first-dose treatment on May 31st, 2024. This study is a multicenter, open-label phase I clinical trial designed to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506 for the treatment of hematologic malignancies. The study will be conducted in two stages, dose escalation and dose expansion, with plans to enroll at least 60 patients. The principal investigator is Wang Jianxiang, a hematologist from the Chinese Academy of Medical Sciences.